IL287919B1 - Chemical process - Google Patents
Chemical processInfo
- Publication number
- IL287919B1 IL287919B1 IL287919A IL28791921A IL287919B1 IL 287919 B1 IL287919 B1 IL 287919B1 IL 287919 A IL287919 A IL 287919A IL 28791921 A IL28791921 A IL 28791921A IL 287919 B1 IL287919 B1 IL 287919B1
- Authority
- IL
- Israel
- Prior art keywords
- compound
- formula
- salt
- hydroxypyrrolidin
- pyrazol
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
WO 2020/230100 PCT/IB2020/054629 CHEMICAL PROCESS Field of invention The present invention relates to a novel chemical process for the synthesis of the compound N-[4-(Chlorodifluoromethoxy)phenyl]-6-[(3R)-3-hydroxypyrrolidin-1-yl]-5-(1H-pyrazol-5- yl)pyridine-3-carboxamide.
Background of the invention The compound N-[4-(Chlorodifluoromethoxy)phenyl]-6-[(3R)-3-hydroxypyrrolidin-1 -yl]-5-(1 H- pyrazol-5-yl)pyridine-3-carboxamide, herein also referred as compound of formula (1), is a BCR-ABL (breakpoint cluster region-Abelson chimeric protein) tvrosine-kinase inhibitor. WO 2013/171639 A1 provides compounds of Formula (1) as useful in treating diseases which respond to inhibition of the tyrosine kinase enzymatic activity of the Abelson protein (ABL1), the Abelson-related protein (ABL2) and related chimeric proteins, in particular BCR- ABL1. The compound of Formula (1) is also known as (R)-N-(4-(chlorodifluoromethoxy)phenyl)-6-(3-hydroxypyrrolidin-1-yl)-5-(1H-pyrazol-5-yl)nicotinamide, or asciminib.
The compound of Formula (1), preparation of the compound of formula (1), and pharmaceutical compositions of the compound of formula (1) are originally described in WO 2013/171639 A1 as Example 9.
Nevertheless, there remains a need to provide improved processes for the preparation of the compound of formula (1), which are economically more efficient, safer, and better suited for full size production scale.
Description of the invention WO 2020/230100 PCT/IB2020/054629 The present invention is directed to an improved synthesis of compound of formula (1) and its purification, using less hazardous chemicals and/or reaction conditions, generating less waste and providing a reproducible process that is easier to handle on production scale. The present invention is also directed to a more efficient means of generating the compound of formula (1) at higher yield and in higher purity, generates less byproducts, and requires a lower catalyst loading compared to the methods disclosed in the prior art.
In this regard, the present invention is provided in the following aspects.
In accordance with a first aspect of the present invention, there is provided a process for producing the compound of formula (1), or a salt, solvate, stereoisomer, complex, co-crystal, ester, or oxazoline thereof, comprising the step of reacting the compound of formula (2), O v"i0H(2),or a salt, solvate, stereoisomer, complex, co-crystal, ester or oxazoline thereof; and the compound of formula (3), or 1-(tetrahydro-2H-pyran-2-yr)-1H-pyrazole-5-boronic acid, pinacol esterwith an alkali or alkaline salt in the presence of a metal complex catalyst to obtain the compound of formula (1) or a salt, solvate, stereoisomer, complex, co-crystal, ester or oxazoline thereof, preferably to obtain compound of formula (1) is in its free carboxylic acid form.
WO 2020/230100 PCT/IB2020/054629 In the process, according to first aspect, the metal complex catalyst may be a metal precursor and a ligand or a pre-formed metal complex catalyst comprising a metal M and a ligand.
The metal M may be selected from Cu (copper) and Pd (palladium). Preferably the metal M is Pd.
The metal precursor may be selected from M(OAc)2, M2(dba)3, [M(C3H5)CI]2 (allyl metal chloride dimer), M(TFA)2, M(MeCN)2CI2, MCI2, [(cinnamyl)MCI]2, [MCI]2 (metal chloride), and M(acac)2. Preferably the metal precursor is [MCI]2 (metal chloride).
The ligand may be selected from Cy3P, (2-MeOPh)3P, P(tBu)2-n-PrSO2H, Q-phos (1,2,3,4,5- pentaphenyl-T-(di-tert-butylphosphino)ferrocene) , CataCXium ABn (Did- adamantyl)benzylphosphine), CataCXium A (Di(l-adamantyl)-n-butylphosphine), and S-Phos (2-Dicyclohexylphosphino-2',6'-dimethoxybiphenyl). Preferably, the ligand is S-Phos.
The pre-formed metal complex catalyst may be composed of the metals as ligands as defined above oris selected from [(o-tol)3P]2PdCI2] [t-Bu3PPdBr]2 / Pd-113, (dtbpf)PdCI2 / Pd-118, PEPPSI, PdCI2(PPh3)2, Pd(tBu2PhP)2, Pd(dppf)CI2 ■ CH2CI2, [(t-Bu)3P]Pd(0), CataCXium C, Pd(tBu2PhP)2(Pd-122), Pd(dppf)CI2 ■ CH2CI2 (Pd-106), (2-MeOPh)3P/ Pd2(dba)3, and PdCI2(Amphos)2! Pd-132. Preferably, the pre-formed metal complex catalyst is selected from (dtbpf)PdCI2 (Pd-118), Pd(tBu2PhP)2(Pd-122), Pd(dppf)CI2 ■ CH2CI2 (Pd-106) and (2-MeOPh)3P/ Pd2(dba)3.
The alkali or alkaline salt may be selected from Na2CO3, CS2CO3, K3PO4, KF, and K2CO3. Preferably, the alkaline salt is K2CO3.
WO 2013/171639 A1, Example 9 describes a similar process in Stage 9.5 whereby the pre- formed metal complex catalyst Pd(PPh3)2CI2 and alkali salt K3PO4 in toluene are used to yield intermediate methyl 6-((R)-3-hydroxypyrrolidin-1-yl)-5-(1-(tetrahydro-2H-pyran-2-yl)-1 H- pyrazol-5-yl)nicotinate. However, when scaled up to 3 kg, the synthesis resulted in incomplete conversion of starting materials and required additional amounts of the compound of formula (3) and K3PO4 to complete the reaction, thus not suitable for large scale manufacturing of the compound of formula (1).
WO 2020/230100 PCT/IB2020/054629 The reaction provided herein provides a high rate of conversion [> 98 % conversion to the compound of formula (1)] and a high purity [> 96 % purity measured as in-process control (IPC)]. The compound of formula (1) is obtained in high yield (> 80%).An advantage of this process over the prior art process is the reduction of byproducts produced and catalyst loading required fora more complete conversion of starting materials. Therefore, the process of the invention suitable for scaling up for commercial production purposes.In accordance with a second aspect of the invention, there is provided the process according to first aspect, further comprising the step of reacting the compound of formula (4) (4),or a salt, solvate, stereoisomer, complex, co-crystal, ester or oxazoline thereof, preferablythe compound of formula (4) is in its free methyl ester form; with the compound of formula (5), to obtain the compound of formula (6) (6), WO 2020/230100 PCT/IB2020/054629 or a salt, solvate, stereoisomer, complex, co-crystal, ester or oxazoline thereof, preferably the compound of formula (6) is in its free carboxylic acid form.
WO 2013/171639 A1, Example 9 describes a similar process in alternate Stage 9.1 by substituting a compound of formula (4) with 6-((R)-3-hydroxypyrrolidin-1-yl)-5-(1-(tetrahydro- 2H-pyran-2-yl)-1H-pyrazol-5-yl)nicotinic acid in NMM and combining with HOBtH2O and EDCIHCI in THE. However, 6-((R)-3-hydroxypyrrolidin-1-yl)-5-(1-(tetrahydro-2H-pyran-2-yl)- H-pyrazol-5-yl)nicotinic acid was found difficult to crystallize, extract, and deliver consistent yield from the reaction. The synthesis also resulted in problematic impurities that are difficult to eliminate and negatively impacted yield.
An advantage of the process disclosed herein over the prior art process is that it avoids the problems found with 6-((R)-3-hydroxypyrrolidin-1-yl)-5-(1-(tetrahydro-2H-pyran-2-yl)-1H- pyrazol-5-yl)nicotinic acid and delivers consistent yield of the compound of formula (6). Therefore, the process of the invention is suitable for scaling up for commercial production purposes.
Examples Example 1: Step D2 + D3 -> D4 D3 C-14H23BN2O3278.16 PdCI2(dtbof) K2CO3 372.42Basic procedure: A mixture of (R)-methyl 5-bromo-6-(3-hydroxypyrrolidin-1-yl)nicotinate (45.6 kg, D2), 1-1- (tetrahydro-2H-pyran-2-yl)-1H-pyrazole-5-boronic acid, pinacol ester (50.5 kg, D3), and K2CO3 (41.8 kg) in toluene (282 mb) was added to a dry vessel. The suspension was stirred and water was added. PdCI2(dtbpf) (500 g) was added and the suspension was stirred at WO 2020/230100 PCT/IB2020/054629 about 50 °C until full conversion was achieved. After reaction completion, QuadraSil MP was added to the reaction mixture. The solid residues were removed by filtration over activated charcoal filter and the filter residue was washed with toluene, potable water and again with toluene. The organic and aqueous phases were separated and the aqueous layer was washed with toluene. The combined organic layers were washed with sodium chloride solution, dried using [Na2SO4] and evaporated in situ to provide methyl 6-((R)-3- hydroxypyrrolidin-1-yl)-5-(1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-5-yl)nicotinate (D4). Yield of D4 was estimated to be about 54 kg D4 / kg D2 (~ 95 %).
Example 2: Step D4 + D5 -> D6 D4 C19H24N4O4372.42 193.58 + 36.46 D6 C25H26CIF2N504533.95 To an empty vessel, a solution of sodium hydroxide (15.8 kg) and water was added to a mixture of 31.6 kg 4-(chlorodifluoromethoxy)aniline HCI (D5) in methyltetrahydrofuran (3kg) and the reaction mixture was stirred at around 25 °C. The biphasic mixture was separated and the organic phase was washed twice with water. The organic phase was concentrated by distillation, followed by addition of fresh methyltetrahydrofuran (2 x 148 kg) to obtain a concentrated solution of 4-(chlorodifluoromethoxy)aniline in methyltetrahydrofuran.
To the 10-20% solution of 660 kg of methyl 6-((R)-3-hydroxypyrrolidin-1-yl)-5-(1-(tetrahydro- 2H-pyran-2-yl)-1 H-pyrazol-5-yl)nicotinate (D4) in toluene, methyltetrahydrofuran (239 kg) was added and the solution was concentrated by distillation. To this concentrated solution, 148 kg of concentrated solution of D5 in methyltetrahydrofuran was added. To the obtained a mixture, 20% potassium tert-butoxide (258 kg) in tetra hydrofuran (169 kg) was dosed at around 25 °C. After reaction completion, aqueous sodium chloride solution (602 kg) was added and biphasic mixture was separated. The organic phase was extracted with aqueous WO 2020/230100 PCT/IB2020/054629 sodium chloride (602 kg) solution. The organic layer was filtered over activated charcoal filter. The solvent was exchanged by distillation from methyltetrahydrofuran to isopropanol. To this solution, seed crystals of N2(42(Chlorodifluorgme^hydroxypyrrolidin-1-yl)-5-(1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-5-yl)nicotinamide (0.16 kg, D6) were added, followed by n-heptane (1274 kg). D6 was collected by filtration, washed with a mixture of n-heptane and isopropanol and dried under vacuum. Yield of D6 was estimated to be about 79-87 % of D6 based on amount of D3 charged.
Example 3: Step D6 -> Al C25H26CIF2N5O4533.95 Al C20H18CIF2N5O3449.84To a suspension of N-(4-(Chlorodifluoromethoxy)phenyl)-6-((R)-3-hydroxypyrrolidin-1-yl)-5- (1-(tetrahydro-2H-pyran-2-yl)-1 H-pyrazol-5-yDnicotinamide (39.1kg, D6) in methanol (3kg), 37% HCI solution (9 kg) was added at 22°C (pH < 1). The clear solution was then stirred for 1 h at 22 °C (IPC). The mixture was then quenched with 30% NaOH (4 kg) (pH = 10). Water was added to the mixture and the pH was adjusted to 2.5 to 3.0 by the addition of 30% NaOH. The solution was filtered over an active charcoal filter and then the pH was adjusted to 3.0 - 3.5 by the addition of more 30% sodium hydroxide before seeding with N-(4- (Chlorodifluoromethoxy)phenyl)-6-(3-hydroxypyrrolidin-1-yl)-5-(1H-pyrazol-5-yl)nicotinamide (0.027kg, Al). A final pH adjustment to pH 7.5 - 9.0 was performed by the addition of ca. 1% sodium hydroxide solution resulting in precipitation of the product. The suspension was cooled to 10 °C and stirred before the product A1 was isolated by filtration, washed with a 4:mixture of water/methanol and dried. Yield of A1 was estimated to be about 76%.
Example 4: A1 -> A1a WO 2020/230100 PCT/IB2020/054629 A mixture of N-(4-(Chlorodifluoromethoxy)phenyl)-6-(3-hydroxypyrrolidin-1-yl)-5-(1H-pyrazol- 5-yl)nicotinamide (29.2 kg, A1), methanol (190 kg), and 37% hydrochloric acid (7 kg) is heated to about 50 °C and the resulting solution was filtered. The first portion of t-butyl methyl ether TBME (146 kg) and seed crystals of N-(4-(Chlorodifluoromethoxy)phenyl)-6-(3- hydroxypyrrolidin-1-yl)-5-(1H-pyrazol-5-yl)nicotinamide hydrochloride (0.26 kg, A1a) were added at about 50 °C to the filtrate. The second portion of TBME (271 kg) was added and the suspension cooled to about 0 °C and stirred to allow for completion of crystallization. A1a was collected by filtration, washed with a mixture of TBME (78 kg) and methanol (9 kg) and dried under vacuum. Yield of A1a was estimated to be about 96%.
Claims (3)
1. - 9 - 287919/ CLAIMS 1. A process for producing the compound of formula (1), N ONHN NHNO OH FFCl (1), or a salt thereof, comprising the step of reacting the compound of formula (2), (2), or a salt thereof; and the compound of formula (3), (3), with an alkali or alkaline salt in the presence of a metal complex catalyst to obtain the compound of formula (4) or a salt thereof, - 10 - 287919/ (4), wherein the alkali or alkaline salt is K 2CO 3 and the metal complex catalyst is (dtbpf)PdCl2.
2. A process according to claim 1, further comprising the step of reacting the compound of formula (4) or a salt thereof, with the compound of formula (5), (5), or a salt thereof.
3. A process according to claim 1 for producing the compound of formula (1), N ONHN NHNO OH FFCl (1), or a salt thereof, comprising the step of reacting the compound of formula (2), (2), or a salt thereof; and the compound of formula (3), - 11 - 287919/ (3), with an alkali or alkaline salt in the presence of a metal complex catalyst to obtain the compound of formula (4) or a salt thereof, (4), wherein the alkali or alkaline salt is K2CO3 and the metal complex catalyst is (dtbpf)PdCl 2, further comprising the step of reacting the compound of formula (4) or a salt thereof, with the compound of formula (5), (5), or a salt thereof, to obtain a compound of formula (6): 15 - 12 - 287919/ and reacting the compound of formula (6) with HCl to obtain the compound of formula (1).
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962848869P | 2019-05-16 | 2019-05-16 | |
| US201962929995P | 2019-11-04 | 2019-11-04 | |
| PCT/IB2020/054629 WO2020230100A1 (en) | 2019-05-16 | 2020-05-15 | Chemical process |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| IL287919A IL287919A (en) | 2022-01-01 |
| IL287919B1 true IL287919B1 (en) | 2025-09-01 |
| IL287919B2 IL287919B2 (en) | 2026-01-01 |
Family
ID=70775450
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL287919A IL287919B2 (en) | 2019-05-16 | 2020-05-15 | Chemical process |
| IL322253A IL322253A (en) | 2019-05-16 | 2020-05-15 | Chemical process |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL322253A IL322253A (en) | 2019-05-16 | 2020-05-15 | Chemical process |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US11236070B2 (en) |
| EP (1) | EP3969445B1 (en) |
| JP (1) | JP7620572B2 (en) |
| KR (1) | KR102875297B1 (en) |
| CN (1) | CN114096529A (en) |
| AU (1) | AU2020275137B2 (en) |
| CA (1) | CA3140119A1 (en) |
| ES (1) | ES3014254T3 (en) |
| IL (2) | IL287919B2 (en) |
| SI (1) | SI3969445T1 (en) |
| WO (1) | WO2020230100A1 (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022206937A1 (en) * | 2021-04-01 | 2022-10-06 | 苏州晶云药物科技股份有限公司 | New crystal form of hydrochloride of pyrazole-substituted nicotinamide compound and preparation method therefor |
| CN116135851B (en) * | 2021-11-17 | 2025-09-23 | 武汉众诚康健生物医药科技有限公司 | Aromatic amine compound and its application |
| CN114369085B (en) * | 2021-12-27 | 2023-01-03 | 武汉九州钰民医药科技有限公司 | Preparation method of Asciminib hydrochloride |
| EP4615831A1 (en) * | 2022-11-10 | 2025-09-17 | Synthon B.V. | Crystalline form of asciminib hydrochloride |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013171639A1 (en) * | 2012-05-15 | 2013-11-21 | Novartis Ag | Benzamide derivatives for inhibiting the activity of abl1, abl2 and bcr-abl1 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2117662A1 (en) | 1971-04-10 | 1972-10-19 | Farbwerke Hoechst AG, vormals Meister Lucius & Brüning, 6000 Frankfurt | Phenylurea derivatives, their production and use as herbicides |
| JPH02104571A (en) | 1988-10-13 | 1990-04-17 | Kanegafuchi Chem Ind Co Ltd | Production of n-benzylpyrrolidine derivative |
| JPH02212469A (en) | 1989-02-10 | 1990-08-23 | Kanegafuchi Chem Ind Co Ltd | Production of n-benzylpyrrolidine derivative or its salt |
| US5739342A (en) | 1997-03-03 | 1998-04-14 | Abbott Laboratories | Process for the preparation of nicotinic acids |
| US5916910A (en) | 1997-06-04 | 1999-06-29 | Medinox, Inc. | Conjugates of dithiocarbamates with pharmacologically active agents and uses therefore |
| GB0309631D0 (en) | 2003-04-28 | 2003-06-04 | Bayer Cropscience Ag | Novel process for the preparation of 2-aminomethylpyridine derivatives |
| EP1674455A1 (en) | 2004-12-21 | 2006-06-28 | Bayer CropScience S.A. | Process for the preparation of a 2-ethylaminopyridine derivative |
| ES2326280T3 (en) | 2005-04-06 | 2009-10-06 | F. Hoffmann-La Roche Ag | DERIVATIVES OF PIRIDIN-3-CARBOXAMIDE AS INVESTED AGONISTS OF CB1. |
| WO2009151991A1 (en) | 2008-06-11 | 2009-12-17 | Merck & Co., Inc. | Pyrazole derivatives useful as inhibitors of faah |
| US20120101282A1 (en) | 2010-10-22 | 2012-04-26 | Pascal Dott | Process for the preparation of nicotinamide derivatives |
| JP2013095742A (en) | 2011-11-07 | 2013-05-20 | Manac Inc | Method of producing bromopyridine derivative |
| KR20150008406A (en) | 2012-05-15 | 2015-01-22 | 노파르티스 아게 | Benzamide derivatives for inhibiting the activity of abl1, abl2 and bcr-abl1 |
| CN104119238B (en) | 2013-04-26 | 2016-09-21 | 金凯(辽宁)化工有限公司 | A kind of preparation method of 4-(a chlorine difluoro-methoxy) aniline |
| DK3120852T3 (en) * | 2015-01-30 | 2019-07-29 | Taiho Pharmaceutical Co Ltd | PREVENTIVE AND / OR THERAPEUTIC AGENT FOR IMMUNE DISEASES |
| MY185488A (en) | 2015-04-09 | 2021-05-19 | Orion Corp | Process for the preparation of androgen receptor antagonists and intermediates thereof |
| TWI726900B (en) | 2015-08-04 | 2021-05-11 | 美商陶氏農業科學公司 | Process for fluorinating compounds |
| KR101830372B1 (en) | 2015-09-01 | 2018-02-20 | 삼성전자주식회사 | Refrigerator |
| EP3416949A1 (en) * | 2016-02-18 | 2018-12-26 | Solvay Sa | Process for the manufacture of carboxamides |
| KR101825065B1 (en) * | 2016-05-24 | 2018-02-05 | 한국화학연구원 | Pharmaceutical composition for inducing the degradation of ALK protein and pharmaceutical composition for use in preventing or treating cancer containing the same as an active ingredient |
| US11353435B2 (en) | 2018-05-24 | 2022-06-07 | Iowa State University Research Foundation, Inc. | Zwitterionic compounds as gas chromatographic column stationary phases |
| LT3841101T (en) | 2018-08-24 | 2023-06-26 | Bayer Aktiengesellschaft | Method for preparing 2-[(3r)-3-methylmorpholin-4-yl]-4-[1-methyl-1h-pyrazol-5-yl)-8-(1h-pyrazol-5-yl)-1,7-naphthyridine |
-
2020
- 2020-05-14 US US16/874,613 patent/US11236070B2/en active Active
- 2020-05-15 WO PCT/IB2020/054629 patent/WO2020230100A1/en not_active Ceased
- 2020-05-15 CN CN202080050370.XA patent/CN114096529A/en active Pending
- 2020-05-15 IL IL287919A patent/IL287919B2/en unknown
- 2020-05-15 CA CA3140119A patent/CA3140119A1/en active Pending
- 2020-05-15 ES ES20726960T patent/ES3014254T3/en active Active
- 2020-05-15 SI SI202030586T patent/SI3969445T1/en unknown
- 2020-05-15 EP EP20726960.6A patent/EP3969445B1/en active Active
- 2020-05-15 IL IL322253A patent/IL322253A/en unknown
- 2020-05-15 JP JP2021568211A patent/JP7620572B2/en active Active
- 2020-05-15 AU AU2020275137A patent/AU2020275137B2/en active Active
- 2020-05-15 KR KR1020217040724A patent/KR102875297B1/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013171639A1 (en) * | 2012-05-15 | 2013-11-21 | Novartis Ag | Benzamide derivatives for inhibiting the activity of abl1, abl2 and bcr-abl1 |
Also Published As
| Publication number | Publication date |
|---|---|
| SI3969445T1 (en) | 2025-05-30 |
| KR20220009415A (en) | 2022-01-24 |
| EP3969445B1 (en) | 2024-11-27 |
| CA3140119A1 (en) | 2020-11-19 |
| IL322253A (en) | 2025-09-01 |
| KR102875297B1 (en) | 2025-10-23 |
| AU2020275137A1 (en) | 2021-12-16 |
| JP2022532232A (en) | 2022-07-13 |
| ES3014254T3 (en) | 2025-04-21 |
| US20200361903A1 (en) | 2020-11-19 |
| IL287919B2 (en) | 2026-01-01 |
| IL287919A (en) | 2022-01-01 |
| WO2020230100A9 (en) | 2024-08-22 |
| EP3969445A1 (en) | 2022-03-23 |
| CN114096529A (en) | 2022-02-25 |
| JP7620572B2 (en) | 2025-01-23 |
| US11236070B2 (en) | 2022-02-01 |
| WO2020230100A1 (en) | 2020-11-19 |
| AU2020275137B2 (en) | 2023-06-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7620572B2 (en) | Chemical Process | |
| EP2687510B1 (en) | Method for preparing 2,3-dichloropyridine | |
| WO2010091877A2 (en) | Process for producing ambrisentan | |
| KR101420892B1 (en) | Process for the preparation of Imatinib and intermediates thereof | |
| AU2007337255A1 (en) | Novel intermediate and process useful in the preparation of {2-[1-(3,5-bis-trifluoromethyl-benzyl)-5-pyridin-4-yl-1H-[1,2,3]triazol-4-yl]-pyridin-3-yl} -(2-chlorophenyl)-methanone | |
| CA2988594C (en) | Methods of making protein deacetylase inhibitors | |
| JP2024037935A5 (en) | ||
| KR20160144402A (en) | Novel manufacturing process for triazine, pyrimidine and pyridine derivatives | |
| CZ203394A3 (en) | Process for preparing fibrinogen receptor antagonizing matters | |
| JP2022523986A (en) | 4-Amino-5-Methyl-1H-Pyridine-2 from 2-Chloro-5-Methyl-4-nitro-Pyridine-1-oxide using Intermediate Compound 2-Chloro-5-Methyl-4-pyridinamine Synthesis of (1H) -one (intermediate compound for synthesizing MR antagonist finelenone) | |
| JP2019516669A (en) | Method of preparing AD-35 | |
| RU2820241C2 (en) | Chemical method | |
| KR100574350B1 (en) | Method for preparing 2-aminopyridine derivative | |
| EA016832B1 (en) | Process for the preparation of 5-(2-ethyl-2,3-dihydro-1h-inden-2-yl)-1h-imidazole and salts thereof | |
| HK40061249B (en) | Process for the preparation of n-[4-(chlorodifluoromethoxy)phenyl]-6-[(3r)-3-hydroxypyrrolidin-1-yl]-5-(1h-pyrazol-5-yl)pyridine-3-carboxamide | |
| HK40061249A (en) | Process for the preparation of n-[4-(chlorodifluoromethoxy)phenyl]-6-[(3r)-3-hydroxypyrrolidin-1-yl]-5-(1h-pyrazol-5-yl)pyridine-3-carboxamide | |
| CN110023316A (en) | Prepare the chemical method of imidazo pyrrolidinone derivatives and its intermediate | |
| WO2021009034A1 (en) | 3-[2(r)-amino-2-phenylethyl]-5-(2-fluoro-3-methoxyphenyl)-1-[2-fluoro-6-(trifluoromethyl)benzyl]-6-methyl-1h-pyrimidine-2,4(1h,3h)-dione hydrochloride salt (i) in solid form, process for preparing same, and use thereof in the synthesis of elagolix | |
| AU2016387566A1 (en) | An improved process for the preparation of Regorafenib | |
| JP7373241B2 (en) | Method for producing pyrimidinyl bipyridine compounds and intermediates therefor | |
| CN109810052B (en) | Simple and convenient preparation method of high-selectivity apatinib | |
| CA2703465A1 (en) | Synthesis and crystalline forms of cb-1 antagonist/inverse agonist | |
| US20040063960A1 (en) | Process of preparing 3S-3-amino-3-aryl propionic acid and derivatives thereof | |
| NZ514379A (en) | Synthesis of 3-amino-3-aryl propanoates | |
| JP2003137835A (en) | Method for producing (r)-3-hydroxy-3-(2-phenyl)hexanoic acid |